×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:ABIO

ARCA biopharma Stock Forecast, Price & News

$2.48
-0.01 (-0.40%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.40
$2.49
50-Day Range
$2.24
$2.53
52-Week Range
$1.71
$3.84
Volume
43,706 shs
Average Volume
45,770 shs
Market Capitalization
$35.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ARCA biopharma MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$1.09 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.66 out of 5 stars

Medical Sector

1184th out of 1,412 stocks

Diagnostic Substances Industry

19th out of 27 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ARCA biopharma logo

About ARCA biopharma (NASDAQ:ABIO) Stock

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

ABIO Stock News Headlines

ARCA biopharma (NASDAQ:ABIO) Now Covered by StockNews.com
ARCA biopharma GAAP EPS of -$0.23
Albioma : Governance changes
ARCA biopharma, Inc. Common Stock (ABIO)
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABIO
Employees
17
Year Founded
N/A

Company Calendar

Last Earnings
5/02/2022
Today
7/03/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Profitability

Net Income
$-19.32 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.54 per share

Miscellaneous

Free Float
14,341,000
Market Cap
$35.74 million
Optionable
Not Optionable
Beta
2.03














ARCA biopharma Frequently Asked Questions

How has ARCA biopharma's stock price performed in 2022?

ARCA biopharma's stock was trading at $2.15 at the beginning of the year. Since then, ABIO shares have increased by 15.3% and is now trading at $2.48.
View the best growth stocks for 2022 here
.

When is ARCA biopharma's next earnings date?

ARCA biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for ARCA biopharma
.

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) released its quarterly earnings data on Monday, May, 2nd. The biopharmaceutical company reported ($0.23) EPS for the quarter.
View ARCA biopharma's earnings history
.

Who are ARCA biopharma's key executives?

ARCA biopharma's management team includes the following people:
  • Dr. Michael R. Bristow M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 77, Pay $363.56k)
  • Mr. Thomas A. Keuer, Chief Operating Officer (Age 63, Pay $360.58k)
  • Mr. Christopher D. Ozeroff, Sr. VP, Gen. Counsel & Sec. (Age 63, Pay $318.86k)
  • Mr. C. Jeffrey Dekker CPA, Chief Financial Officer (Age 57)
  • Dr. Debra Marshall FACC, M.D., Chief Medical Officer

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma CEO Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among ARCA biopharma's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

How do I buy shares of ARCA biopharma?

Shares of ABIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARCA biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $2.48.

How much money does ARCA biopharma make?

ARCA biopharma (NASDAQ:ABIO) has a market capitalization of $35.74 million. The biopharmaceutical company earns $-19.32 million in net income (profit) each year or ($1.300010) on an earnings per share basis.

How many employees does ARCA biopharma have?

ARCA biopharma employs 17 workers across the globe.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The official website for ARCA biopharma is arcabio.com. The biopharmaceutical company can be reached via phone at (720) 940-2200, via email at derek.cole@arcabio.com, or via fax at 720-208-9261.

This page (NASDAQ:ABIO) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.